Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

NCT: NCT04816604 · ACTIVE_NOT_RECRUITING

NCT IDNCT04816604
StatusACTIVE_NOT_RECRUITING
Start Date2021-04-05
Completion2027-12

Brief Summary

This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.

Frequently Asked Questions

What is Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)?

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) is a clinical trial registered under NCT04816604. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04816604?

The current status of NCT04816604 (Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)) is: ACTIVE_NOT_RECRUITING.

When did Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) start?

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) started on 2021-04-05.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑